AAAAAA

   
Results: 1-10 |
Results: 10
EFFECTS OF FENSPIRIDE ON HUMAN BRONCHIAL CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES - FUNCTIONAL AND BIOCHEMICAL-STUDY
Authors: CORTIJO J NALINE E ORTIZ JL BERTO L GIRARD V MALBEZIN M ADVENIER C MORCILLO EJ
Citation: J. Cortijo et al., EFFECTS OF FENSPIRIDE ON HUMAN BRONCHIAL CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES - FUNCTIONAL AND BIOCHEMICAL-STUDY, European journal of pharmacology, 341(1), 1998, pp. 79-86
NEUROPSYCHOPHYSIOLOGICAL EVALUATION OF 3 DOSES OF S-12024-2 IN MILD-TO-MODERATE ALZHEIMERS-DISEASE
Authors: DEROUESNE C RENAULT B VANDERLINDEN M LACOMBLEZ L HOMEYER P OUSS L NEUMAN E MALBEZIN M BARRANDON S GUEZ D
Citation: C. Derouesne et al., NEUROPSYCHOPHYSIOLOGICAL EVALUATION OF 3 DOSES OF S-12024-2 IN MILD-TO-MODERATE ALZHEIMERS-DISEASE, Clinical drug investigation, 14(4), 1997, pp. 301-306
PREJUNCTIONAL AND POSTJUNCTIONAL INHIBITORY EFFECTS OF FENSPIRIDE ON GUINEA-PIG BRONCHI
Authors: GIRARD V NALINE E CRAMBES O MALBEZIN M MALSTROM RE LUNDBERG JM ADVENIER C
Citation: V. Girard et al., PREJUNCTIONAL AND POSTJUNCTIONAL INHIBITORY EFFECTS OF FENSPIRIDE ON GUINEA-PIG BRONCHI, The European respiratory journal, 10(5), 1997, pp. 1015-1020
BRIDGING STUDY OF S12024 IN 53 INPATIENTS WITH ALZHEIMERS-DISEASE
Authors: ALLAIN H NEUMAN E MALBEZIN M SALZMAN V GUEZ D WESNES K GANDON JM
Citation: H. Allain et al., BRIDGING STUDY OF S12024 IN 53 INPATIENTS WITH ALZHEIMERS-DISEASE, Journal of the American Geriatrics Society, 45(1), 1997, pp. 125-126
ASSESSMENT OF CEREBROVASCULAR-DISEASE WITH POSITRON EMISSION TOMOGRAPHY - ATTEMPT OF AN IN-VIVO MODEL FOR TREATMENT EVALUATION OF BRAIN GLUCOSE-METABOLISM
Authors: CINOTTI L CROISILE B LAURENT B LEBARS D MALBEZIN M MAUGUIERE F
Citation: L. Cinotti et al., ASSESSMENT OF CEREBROVASCULAR-DISEASE WITH POSITRON EMISSION TOMOGRAPHY - ATTEMPT OF AN IN-VIVO MODEL FOR TREATMENT EVALUATION OF BRAIN GLUCOSE-METABOLISM, European neurology, 35, 1995, pp. 17-22
THERAPEUTIC BENEFIT OF A LOW-DOSAGE OF IN DAPAMIDE - RESULT OF A DOUBLE-BLIND, PLACEBO-CONTROLLED EUROPEAN STUDY
Authors: ASMAR R GUEZ D MALBEZIN M BRAULT Y DECORDOUE A BARRANDON S BRUXELLES MC CHASTANG C
Citation: R. Asmar et al., THERAPEUTIC BENEFIT OF A LOW-DOSAGE OF IN DAPAMIDE - RESULT OF A DOUBLE-BLIND, PLACEBO-CONTROLLED EUROPEAN STUDY, Archives des maladies du coeur et des vaisseaux, 88(8), 1995, pp. 1083-1087
THE AGE-ASSOCIATED MEMORY IMPAIRMENT CONSTRUCT REVISITED - COMMENTS AND RECOMMENDATIONS OF A FRENCH-SPEAKING WORKGROUP
Authors: DEROUESNE C KALAFAT M GUEZ D MALBEZIN M POITRENAUD J
Citation: C. Derouesne et al., THE AGE-ASSOCIATED MEMORY IMPAIRMENT CONSTRUCT REVISITED - COMMENTS AND RECOMMENDATIONS OF A FRENCH-SPEAKING WORKGROUP, International journal of geriatric psychiatry, 9(7), 1994, pp. 577-587
CLINICAL AND NEUROPHYSIOLOGICAL EVALUATION OF 3 DOSES OF S120242 (50,100, 200 MG OD) DURING REPEATED ORAL-ADMINISTRATION (7 DAYS) IN 12 OUT-PATIENTS WITH MILD-TO-MODERATE ALZHEIMERS-DISEASE
Authors: DEROUESNE C RENAULT B GUEGUEN B VANDERLINDEN M LACOMBLEZ L HOMEYER P OUSS L NEUMAN E MALBEZIN M BARRANDON S GUEZ D
Citation: C. Derouesne et al., CLINICAL AND NEUROPHYSIOLOGICAL EVALUATION OF 3 DOSES OF S120242 (50,100, 200 MG OD) DURING REPEATED ORAL-ADMINISTRATION (7 DAYS) IN 12 OUT-PATIENTS WITH MILD-TO-MODERATE ALZHEIMERS-DISEASE, Neurobiology of aging, 15, 1994, pp. 190000100-190000100
PHARMACODYNAMIC EFFECTS OF REPEATED ORAL-ADMINISTRATION OF 4 DIFFERENT DOSES OF S12024-2 (COGNITIVE ENHANCER) IN 36 HEALTHY ELDERLY VOLUNTEERS
Authors: WESNES K NEUMAN E DEWILDE HJG MALBEZIN M CRIJNS HJMJ JONKMAN JHG GUEZ D
Citation: K. Wesnes et al., PHARMACODYNAMIC EFFECTS OF REPEATED ORAL-ADMINISTRATION OF 4 DIFFERENT DOSES OF S12024-2 (COGNITIVE ENHANCER) IN 36 HEALTHY ELDERLY VOLUNTEERS, Neurobiology of aging, 15, 1994, pp. 190000100-190000100
ACCEPTABILITY AND CLINICAL ACTIVITY OF 4 WEEKS TREATMENT BY S12024-2 IN 53 INPATIENTS WITH MODERATE TO SEVERE ALZHEIMERS-DISEASE
Authors: ALLAIN H WEANES K NEUMAN E GANDON JM SALZMAN V MALBEZIN M GUEZ D
Citation: H. Allain et al., ACCEPTABILITY AND CLINICAL ACTIVITY OF 4 WEEKS TREATMENT BY S12024-2 IN 53 INPATIENTS WITH MODERATE TO SEVERE ALZHEIMERS-DISEASE, Neurobiology of aging, 15, 1994, pp. 190000136-190000137
Risultati: 1-10 |